Hologic to acquire Mobidiag Oy for $795 million

Avance advises Hologic, Inc. in the acquisition of Mobidiag Oy for an enterprise value of approximately $795 million.

Mobidiag Oy is a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation. It develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.